Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 8/2020

01-08-2020 | osteosarcoma | Sarcoma (SH Okuno, Section Editor)

Role of TKI for Metastatic Osteogenic Sarcoma

Author: Florence Duffaud, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 8/2020

Login to get access

Opinion statement

Osteosarcomas (OS) belong to a large family of mesenchymal tumor entities which exhibit heterogenous histological, genetic, and molecular features. Current OS treatment regimen consists of the combination of surgery and intensive multi-agent chemotherapy. Ever since the introduction of chemotherapy, 5-year survival rate among OS patients has improved to 60–75%. However, 30–35% of OS patients are associated with pulmonary metastasis and relapse, which have significantly poor prognosis, with an overall 5-year survival rate of about 20%. The fact that OS are both rare forms of cancer and highly heterogeneous may explain why patients’ survival has not improved in the past three decades, especially for metastatic/relapsed and unresectable osteosarcomas. Patients who experience relapse with metastatic disease have limited therapeutic options, often receiving additional cytotoxic therapy such as ifosfamide and etoposide and/or carboplatin or gemcitabine plus docetaxel. Novel precise OS-targeted thrapies are being developed with the hope of improving metastatic/relapsed OS prognosis. This review provides an overview of the most updated targeted therapies in relapsed/metastatic osteosarcoma and dicusses some clinical options in order to improve progression-free survival.
Literature
1.
Kansara M, Teng MW, Smyth MJ, et al. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–35.PubMed
2.
Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;9:5442–53.PubMed
3.
Lu C, Ding L, Mardis EER, Wilson RKR, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7:104–12.PubMedPubMedCentral
4.
Heymann D. Metastatic osteosarcoma challenged by regorafenib. Lancet Oncol. 2019;20:12–3.PubMed
5.
Bielack SS, Smeland S, Xhelan JS, et al. Methotexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa 2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP. First results of the EURAMOS-1 gooe response randomized controlled yitla. J Clin Oncol. 2015;33:2279–87.PubMedPubMedCentral
6.
Whelan JS. Davis LE/ Osteosarcoma, chondrosarcoma and chordoma. J Clin Oncol. 2018;36:188–93.PubMed
7.
Lagmay JP, Krailo MD, Dang H, et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through CHildren’s Cancer Group. Pediatric Oncology Group and Children’s Oncology Group. Learning form the past to move forward. J Clin Oncol. 2016;34:3031–8.PubMedPubMedCentral
8.
Bone sarcomas: ESMO-PaedCan EURACAN Clinical practice Guidelines for diagnosis, tretaement ad follow-up. Ann Oncol. 2018;29(Suppl 4):iv79–iv95.
9.
NCCN Clinical practice Guidelines in Oncology (NSSN Guidelines). Bone Cancer. Version 1.2020 August 12, 2019. NCCN.org.
10.
Zhang Y, Yang I, Zhao N, et al. Progress in the chemotherapeutic treatment of osteosarcoma (review). Oncol Lett. 2018;16:6228–37.PubMedPubMedCentral
11.
Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, et al. Cell surface receptor expression patterns in osteosarcoma. Cancer. 2012;118:740–9.PubMed
12.
Perry JA, Kiezun A, Tonzi P, van Allen EM, Carter SL, Baca SC, et al. A Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111:E5564–73.PubMedPubMedCentral
13.
Segalini AI, Tellez-Gabriel M, Heymann MF, et al. Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol. 2015;4:1–12.
14.
Blume JP, Hunter T. Oncogenic kinas signalling. Nature. 2001;411:355–65.
15.
16.
• Xie L, Guo W. Anti-angiogenesis target therapy for advanced osteosarcoma (review). Oncol Rep. 2017;38:625–36 Complete and exhaustive review on anti-angiogenesis target therapy for advanced/metastatic osteosarcoma.PubMedPubMedCentral
17.
Chen D, Zhang YJ, Zhu KW, et al. A systematic review of vascualar endothelial growth factor expression as a biomarker of prgnosis in patiens with osteosarcoma. Tumor Biol. 2013;34:1895–9.
18.
Aubry K, Barriere G, Chable-Rabinovitch H, et al. Molecular mechanisms regulating the angiogenic phenotype in tumors; clinical impact in the future. Anticancer Res. 2007;27:3111–9.PubMed
19.
Kuijjer ML, Peterse EFP, van den Akker BEWM, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer. 2013;13:245.PubMedPubMedCentral
20.
Wang H, Han X-D, Qiu Y, Xiong J, et al. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol. 2012;105:235–43.PubMed
21.
Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69:21–7.PubMed
22.
Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781.PubMed
23.
Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer. 2005;41:1349–61.PubMed
24.
Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol. 2001;14:1277–83.PubMed
25.
Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res. 2002;8:788–93.PubMed
26.
O’Day K, Gorlick R. Novel therapeuticc agents for osteosarcoma. Expert Rev Anticancer Ther. 2009;9:511–23.PubMed
27.
Bishop MW, Janeway KA. Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma. F1000 Res. 2016;5:5.
28.
29.
Allen E, Mieville P, Warren CM, et al. Metablic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep. 2016;15:1144–60.PubMedPubMedCentral
30.
Hu C, Deng Z, Zhang Y, Yan L, Cai L, Lei J, et al. The prognostic significance of Src and p-Src expression in patients with osteosarcoma. Med Sci Monit. 2015;21:638–45.PubMedPubMedCentral
31.
32.
Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55:1126–33.PubMed
33.
Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer. 2009;8:118.PubMedPubMedCentral
34.
Fox E, Aplenc R, Bagatell R. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010;28:5174–5181.21060028.PubMedPubMedCentral
35.
Navid F, Baker SD, McCarville MB, et al. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res. 2013;19(1):236–46.PubMed
36.
Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children’s oncology group study. Clin Cancer Res. 2011;17:5113–22.PubMedPubMedCentral
37.
Bender JLG, Lee A, Reid JM, et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report. J Clin Oncol. 2013;31(24):3034–43.
38.
Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncognic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–67.PubMed
39.
Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17:871–9.PubMed
40.
Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors:a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50:254–8.PubMed
41.
Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol. 2012;30:2545–51.PubMedPubMedCentral
42.
Longhi A, Paioli A, Palmerini E, et al. Pazopanib in relapse osteosarcomapatients: report on 15 cases. Acta Oncol. 2019;58:124–8.PubMed
43.
Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unre- sectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sar- coma Group study. Ann Oncol. 2012;23:508–16.PubMed
44.
•• Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20(1):120–33 First published randomized placebo-controlled trial in metastatic/relapsed osteosarcoma showing prolonged progression-free survival with the multitarget antiangiogenesis inhibitor, regorafenib, versus placebo.PubMed
45.
•• Davis L, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37(16):1424–31 Second published randomized placebo-controlled trial in metastatic /relapsed ostosarcoma confirming the activity of regorafenib, in clinically meaningful improvement in progression-free survival versus placebo.PubMed
46.
Italiano A, Penel N, Toulmonde M et al. Cabozantini in patients with advanced osteosarcoma and Ewing sarcoms: a Frenc Sarcoma Group National cancer Institute phase II collaborative study. Ann Oncol. 2018;29(Suppl; AbstrLBAA67).
47.•
Xie L, Xu J, Sun X et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. The Oncologist. 2019;24:e542–e550. www.​TheOncologist.​com. Open-label phase 2 study with Apatinib in advanced osteosarcoma showing a high response rate after failure of chemotherapy, with similar duration of response compared to other antiangiogenesis TKI.
48.
Tian Z, Zhiyuan G, Wang X, et al. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: an observational study. Medicine. 2019;98:19 (e15650).
49.
Gaspar N, Casanova M, Sirvent F et al. Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoppside (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to <25 years with relapsed/refractory osteosarcoma (OS). J Clin Oncol. 2018;36(Suppl Abstr 11,527).
50.
Schuetze SM, Wathen JK. Lucas et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016;122(6):868–74.PubMed
51.
Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16:98–107.PubMed
52.
Schwartz GK, Tap WD, Qin L-X, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013;14:371–82.PubMedPubMedCentral
53.
Wagner LM, Fouladi M, Ahmed A, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015;62:440–4.PubMed
54.
• Martin-Broto RA, Valverde C, et al. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Ann Oncol. 2017;28:2994–9 Single arm phase II study showing that gemcitabine + sirolimus combination is a potentially active regimen in metastatic/relapsed osteosarcoma that could be a safer alternative of gemcitibine and docetaxel.PubMed
55.
Schuetze SM, Zhao L, et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer. 2012;48:1347–53.PubMed
56.
Weigel B. Malempati, Reid, J.M. et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr. Blood Cancer. 2014;61:452–6.
57.
Malempenti S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmackinetic study of cixutumumab in pediatric patients with refractoy solid tumors and Ewing sarcomas: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:256–62.
58.
Baird K, Reinke D, Pressey JG et al. A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung (NCT00752206). J Clin Onol. 2013.31.5 Suppl.tps.10591 asco.​org
59.
Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185–204.PubMedPubMedCentral
60.
Makker V, Rasco DW, Vogelzang NJ et al. Lenvantinib + pembrolizumab in patients with advanced endometrila cancer; Updated results. J Clin Oncol. 2018;36:Suppl Abstr 5596.
61.
Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with renal cancer. A non-randomised, open-label, dose-finding, and dose-expansionphase Ib trial. Lancet Oncol. 2018;19:405–15.PubMedPubMedCentral
62.
Martin-Broto J, Hindi N, Redondo A et al. IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—results of the phase I part. JCO. 2018;36 Suppl abstr 11,515 (ascopubs.​org JCO.2018.16.15_suppl11515).
63.
Fukuoka S, Hara H, Takahashi N et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). JCO. 2018;37:Suppl Abstr 2522 (ascopubs.​org JCO2019.31.15_suppl2522).
Metadata
Title
Role of TKI for Metastatic Osteogenic Sarcoma
Author
Florence Duffaud, MD, PhD
Publication date
01-08-2020
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 8/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-020-00760-w

Other articles of this Issue 8/2020

Current Treatment Options in Oncology 8/2020 Go to the issue

Cardio-oncology (MG Fradley, Section Editor)

Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors

Sarcoma (SH Okuno, Section Editor)

Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone

Upper Gastrointestinal Cancers (JD Berlin, Section Editor)

Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma

Lung Cancer (HA Wakelee and TA Leal, Section Editors)

Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy

Lymphoma (DO Persky, Section Editor)

Hypomethylating Agents in Lymphoma

Upper Gastrointestinal Cancers (JD Berlin, Section Editor)

New Treatment Options for Advanced Biliary Tract Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits